Rapport Therapeutics director granted 15,200 stock options

Rapport Therapeutics, Inc. director Steven M. Paul received a grant of stock options covering 15,200 shares of common stock.

Rhea-AI Filing Summary

Rapport Therapeutics, Inc. director Steven M. Paul received a grant of stock options covering 15,200 shares of common stock. The options carry an exercise price of $35.21 per share and expire on June 10, 2036.

According to the terms, the 15,200 underlying shares will vest on the earlier of June 10, 2027 or the date of the company’s next annual meeting of stockholders, provided he continues to serve through that vesting date. Following this grant, he holds 15,200 stock options directly.

Insider Trade Summary

Grant/Award: 15,200 shares

Grant/Award 1 txn

Insider PAUL STEVEN M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	15,200	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 15,200 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

Key Figures

Options granted: 15,200 options Exercise price: $35.21 per share Underlying shares: 15,200 shares +3 more

6 metrics

Options granted 15,200 options Stock Option (Right to Buy) grant to director

Exercise price $35.21 per share Option exercise price for underlying common stock

Underlying shares 15,200 shares Common stock underlying granted options

Total options after grant 15,200 options Total held directly following this transaction

Vesting date Earlier of June 10, 2027 or next annual meeting Subject to continued service requirement

Expiration date June 10, 2036 Option term end date

Key Terms

Stock Option (Right to Buy), exercise price, underlying security, vesting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 35.2100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

underlying security financial

"underlying_security_title: Common Stock"

vesting financial

"shares underlying this option shall vest upon the earlier of"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Annual Meeting of Stockholders financial

"the date of the next Annual Meeting of Stockholders of the Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Rapport Therapeutics (RAPP) report for Steven M. Paul?

Rapport Therapeutics reported that director Steven M. Paul received a grant of stock options for 15,200 shares. These options give him the right to buy common stock at a fixed price, as part of his equity-based compensation package from the company’s board.

How many stock options did the Rapport Therapeutics (RAPP) director receive?

Steven M. Paul received stock options covering 15,200 shares of Rapport Therapeutics common stock. This entire amount represents a new grant, and after the transaction he directly holds 15,200 stock options tied to the company’s common shares, according to the Form 4 disclosure.

What is the exercise price of the new RAPP stock options granted to the director?

The newly granted stock options to director Steven M. Paul have an exercise price of $35.21 per share. This means he can purchase Rapport Therapeutics common stock at that fixed price once the options vest, regardless of the market price at that time.

When do Steven M. Paul’s Rapport Therapeutics (RAPP) options vest?

The 15,200 stock options will vest on the earlier of June 10, 2027 or the date of Rapport Therapeutics’ next annual meeting of stockholders. Vesting is conditional on his continued service with the company through that vesting date under the grant terms.

What is the expiration date of the new Rapport Therapeutics (RAPP) stock options?

The stock options granted to Steven M. Paul expire on June 10, 2036. After that date, any unexercised options become worthless. The long duration gives him an extended window to decide whether to exercise and purchase common shares at the fixed price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/10/2026 - 05:46 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PAUL STEVEN M

(Last) (First) (Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$35.21	06/10/2026		A		15,200		(1)	06/10/2036	Common Stock	15,200	$0	15,200	D

Explanation of Responses:

1. The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

	/s/ Troy Ignelzi, Attorney-in-Fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)